Aptevo Therapeutics announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon. The Company plans to initiate pre-clinical studies this year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APVO:
